Standard BioTools Ends Illumina Partnership, Sells Mass Cytometry Unit to Multiplex Bio for $5M

Illumina Payment Secures Waiver of Earnout and Royalty Obligations

Standard BioTools disclosed that on July 24, 2026, it entered into a Termination, Waiver and Release Agreement with Illumina, receiving approximately $30 million in cash. In exchange, the company waived rights to earnout payments tied to fiscal year 2026 net revenues from SomaScan assay services and other SOMAmer-based assays, as well as sales of SOMAmer-based array kits and next-generation sequencing library preparation kits. These obligations originated from the Stock Purchase Agreement dated June 22, 2025.

Additionally, Standard BioTools agreed to terminate three agreements established on January 30, 2026, linked to the Illumina Stock Purchase Agreement closing. These included royalty agreements for SOMAmer-based next-generation sequencing kits, a license agreement granting Illumina-specified intellectual property rights for Single SOMAmer development, and another royalty agreement for Single SOMAmers. The Termination Agreement fully settles these future payment obligations in exchange for the lump sum payment.

Mass Cytometry Business Divestiture to Multiplex Bio

On July 28, 2026, Standard BioTools signed a Share and Asset Purchase Agreement with Multiplex Bio Inc. for the acquisition of its mass cytometry business. The total purchase price is $5 million on a cash-free, debt-free basis, subject to standard adjustments. However, no cash will be paid at closing; instead, Multiplex Bio will issue a promissory note bearing 6% interest annually, maturing five years post-closing.

Besides the base price, the agreement includes potential additional consideration of $5 million if Multiplex Bio completes a qualifying sale exceeding a specified threshold within ten years. The exact threshold is undisclosed. Standard BioTools will also provide transition services post-closing under a separate agreement.

Financing and Working Capital Provisions

The agreement mandates Multiplex Bio to make reasonable efforts to secure a senior secured working capital loan on terms acceptable to Standard BioTools. If unsuccessful before closing, Standard BioTools must provide up to $10 million in working capital loans at closing. This contingency ensures operational continuity of the mass cytometry business post-transfer but represents a potential additional capital commitment for Standard BioTools.

Closing Conditions and Stockholder Approval

The transaction’s completion hinges on customary closing conditions plus two critical contingencies: stockholder approval and the successful completion of Standard BioTools’ pending merger with Treeline Biosciences Inc. Both must occur for the mass cytometry sale to close, introducing timing uncertainty.

Ancillary agreements, including the transition services contract, are expected at closing. Delays in stockholder voting or the Treeline merger could impact the transaction’s timeline.

Termination Rights and Deal Protection

Both parties may terminate the agreement if closing does not occur by June 30, 2027, with up to two automatic three-month extensions available. Standard BioTools faces a non-solicitation clause restricting alternative proposals but retains a fiduciary out allowing the board to accept superior unsolicited bids before stockholder approval, subject to Multiplex Bio’s matching rights.

Termination Fees and Expense Reimbursements

If terminated under certain conditions, Standard BioTools must pay Multiplex Bio a $1 million termination fee and reimburse up to $250,000 in out-of-pocket fees if closing misses specified deadlines. Reimbursements offset the termination fee, capping the company’s maximum cash outflow at $1 million.

Strategic Impact of Illumina Settlement and Business Sale

The $30 million Illumina payment removes future contingent liabilities and boosts liquidity, allowing Standard BioTools to reduce exposure to SOMAmer-based products now controlled by Illumina. This likely reflects Illumina’s intent to avoid disputes over earnout or royalty payments after investing in SomaScan technology.

The mass cytometry business sale streamlines operations, signaling management’s view that this segment is non-core, especially with the pending Treeline merger. The $5 million base price plus potential future payments indicates moderate valuation with upside tied to Multiplex Bio’s success.

Balance Sheet Effects and Future Commitments

The Illumina cash inflow strengthens Standard BioTools’ balance sheet by eliminating uncertain earnout and royalty obligations. Conversely, the mass cytometry sale creates contingent liabilities, including the $5 million promissory note with interest and potential $10 million working capital loan. The additional $5 million contingent payment further complicates the financial outlook. Investors should watch future filings for how these are accounted.

Treeline Merger Link and Transaction Timing

The requirement that the Treeline Biosciences merger close before the mass cytometry sale adds complexity. The June 30, 2027 termination deadline gives roughly one year from signing to complete both deals. The filing does not clarify sequencing, but the board’s decision to link these transactions suggests strategic interdependence. Further updates on the Treeline merger are expected in upcoming disclosures.

Forward-Looking Statements and Regulatory Notes

The filing includes forward-looking statements under the Private Securities Litigation Reform Act of 1995, highlighting uncertainties around transaction timing and completion. Stockholder communications under Rule 425 are anticipated ahead of the vote. The filing does not address regulatory approvals such as Hart-Scott-Rodino, implying no significant barriers or separate handling.